转自：证券时报 人民财讯8月28日电，博拓生物(688767)8月28日晚间披露半年报，2025年上半年，公司实现营业收入 2.03亿元，同比下降23.91%；归属于上市公司股东的净利润1240.24万元，同比下降82.82%；基本每股 收益0.07元。报告期内，公司对美业务受关税影响及政府采购减缓导致对美营业收入减少；受周期性波 动影响，国内呼吸道检测产品需求减少以及拉美地区登革热等蚊媒类产品需求减少导致营业收入减少； 注册费用、员工持股计划产生的股份支付费用增加，汇兑收益及利息收入等财务性收益同比减少。 ...

本文来自微信公众号：悟啦无，作者：悟啦无，原文标题：《我，42岁，前战投MD，在一级市场轮 回》，题图来自：AI生成 宝总有近十年的产业经验，包括研发、市场、创业经验。宝总还有近十年的投资经验，涉及VC、PE、 CVC。今年全职FA，从大甲方转变成了乙方，让我们来听听他的心路历程。 以下为宝总自述： 综合这些因素，这样的企业机会就很难碰到，我也不愿意随便找家企业来试错，就直接选择路径最简单 的FA，自己也比较熟悉，过往的资源也可以变现。 听说前一级投资人某省高考状元都去卖保险了，为什么不去尝试下？ 我喜欢一级市场，喜欢和创始人交流技术，用自己的专业知识和行业资源助力他们创业，我会觉得自己 的价值得到实现。卖保险很赚钱，做直播也很赚钱，但都不适合我，也不适合大多数人。苏格拉底曾 说"未经省察的人生不值得活"，没有目的的赚钱会让我抓狂。 我二十年前从北方某大学工科专业毕业，后加入一家准上市公司做了三年多，研发了两款医疗设备。当 时因为研发薪资低、项目周期长，就跳槽到上市公司做市场。我先后做了四年国内、三年海外市场，算 是小有积蓄。 在上市公司的日子过得很舒坦，有闲有钱之后，我就想做一番事业。说服家人之后，我就把工 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company achieved a revenue of 3.065 billion yuan in 2024, representing a year-on-year growth of 10.85%, with a net profit of 562 million yuan, up 15.18% year-on-year [1] - The overseas business is rapidly developing, with a 43% increase in foreign revenue driven by localized operations in developing countries and FDA EUA authorization for respiratory products in North America [2] - The company's diversified business lines show strong growth resilience, with significant contributions from chronic disease management and infectious disease testing [2] - Profitability is steadily improving due to optimized revenue structure and cost control, with a gross margin of 64.15% in 2024, up 1.54 percentage points year-on-year [2] - The company is expected to achieve revenues of 3.476 billion, 3.980 billion, and 4.554 billion yuan from 2025 to 2027, with corresponding net profits of 642 million, 746 million, and 877 million yuan, reflecting growth rates of 14.3%, 16.3%, and 17.5% respectively [2] Summary by Sections Financial Performance - In 2024, the company reported total revenue of 3.065 billion yuan, a 10.85% increase from the previous year, and a net profit of 562 million yuan, marking a 15.18% increase [3] - The gross margin for 2024 was 64.15%, an increase of 1.54 percentage points year-on-year, while the overall net profit margin reached 18.44%, up 0.81 percentage points [2][3] Revenue Breakdown - Domestic revenue was 1.962 billion yuan, down 1.65% year-on-year, while overseas revenue reached 1.103 billion yuan, up 43.23% year-on-year [2] - The chronic disease management testing business generated 1.369 billion yuan, a 22.38% increase, while the infectious disease testing business brought in 1.042 billion yuan, up 9.50% [2] Future Projections - Revenue projections for 2025, 2026, and 2027 are 3.476 billion, 3.980 billion, and 4.554 billion yuan, with year-on-year growth rates of 13.4%, 14.5%, and 14.4% respectively [2][3] - Expected net profits for the same years are 642 million, 746 million, and 877 million yuan, with growth rates of 14.3%, 16.3%, and 17.5% [2][3]